drugset / Trial / NCT05263453
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to Evaluate the Efficacy and Safety of the combination of HL-085 and Vemurafenib in Advanced Melanoma Patients with BRAF V600E/K Mutation. This study includes IIa and IIb phase. Phase IIa will determine the dose regiment for Phase IIb. Phase IIb part will evaluate the efficacy and safety with this combination regiment.
Timeline
- Start
- 2021-09-06
- Primary completion
- 2024-09-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | 12 mg | Oral |
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |